首页 | 本学科首页   官方微博 | 高级检索  
检索        

泮托拉唑钠肠溶胶囊在健康人体的药代动力学和生物等效性
引用本文:杨国荣,李健和,曹俊华,阳巧凤,曾小慧,罗霞.泮托拉唑钠肠溶胶囊在健康人体的药代动力学和生物等效性[J].中国医药导报,2010,7(12):61-63,67.
作者姓名:杨国荣  李健和  曹俊华  阳巧凤  曾小慧  罗霞
作者单位:1. 株洲市二医院药剂科,湖南株洲,412005
2. 中南大学湘雅二医院药学部,湖南长沙,410011
摘    要:目的:评价泮托拉唑钠肠溶胶囊在中国健康志愿者体内的药动学和生物等效性。方法:18名健康男性试验者随机分为2组,分别单剂量口服泮托拉唑钠肠溶胶囊试验制剂或参比制剂40mg。7d清洗期后再交叉给药。于服药前(0h)和服药后0.33、0.67、1.00、1.50、2.00、2.50、3.00、3.50、4.00、6.00、8.00、10.00h抽取静脉血。采用高效液相色谱法测定血浆中泮托拉唑的浓度。通过DASVer2.0软件计算主要药动学参数,评价两制剂的生物等效性。结果:泮托拉唑钠肠溶胶囊试验制剂与参比制剂的tmax分别为(2.60±0.67)h和(2.60±0.50)h,Cmax分别为(2767.90±969.20)μg/L和(2864.10±1090.20)μg/L,t1/2分别为(1.80±0.60)h和(1.80±0.50)h,AUC0→t分别为(8071.1±4747.9)μg.h/L和(8272.5±5095.0)μg.h/L,AUC0→∞分别为(8581.60±5255.70)μg.h/L和(8803.30±5639.10)μg.h/L。以AUC0→t计算,试验制剂中泮托拉唑钠对参比制剂的相对生物利用度为(99.40±11.40)%。结论:经方差分析及双单侧t检验,泮托拉唑钠肠溶胶囊试验制剂与参比制剂在中国健康志愿者体内具有生物等效性。

关 键 词:泮托拉唑钠肠溶胶囊  色谱法  高效液相色谱法  药动学  生物等效性

Pharmacokinetics and bioequivalence of Pantoprazole sodium enteric-coated Capsules in healthy volunteers
YANG Guorong,LI Jianhe,CAO Junhua,YANG Qiaofeng,ZENG Xiaohui,LUO Xia.Pharmacokinetics and bioequivalence of Pantoprazole sodium enteric-coated Capsules in healthy volunteers[J].China Medical Herald,2010,7(12):61-63,67.
Authors:YANG Guorong  LI Jianhe  CAO Junhua  YANG Qiaofeng  ZENG Xiaohui  LUO Xia
Institution:1.Department of Pharmacy,the Second Hospital of Zhuzhou,Zhuzhou 412005,China; 2.Department of Pharmacy,the Second Xiangya Hospital of Central South University,Changsha 410011,China)
Abstract:Objective:To evaluate the pharmacokinetics and bioequivalence of Pantoprazole sodium enteric-coated Capsules in healthy volunteers. Methods:The study was performed in 18 healthy male volunteers according to a randomized 2-way crossover design. The blood samples were collected at 0 h,and 0.33,0.67,1.00,1.50,2.00,2.50,3.00,3.50,4.00,6.00,8.00,10.00 h after taking 40 mg of Pantoprazole sodium enteric-coated Capsules test preparation and reference preparation,and with repeated sampling of the crossover drug administration 7 d after clearance. The concentration of pantoprazole in plasma was determined by HPLC. The pharmacokinetic parameters were calculated and compared statistically to evaluate the relative bioequivalence between the two preparations of pantoprazole sodium by DAS Ver 2.0 software. Results:The major pharmacokinetic parameters of Pantoprazole sodium enteric-coated Capsules test preparation and reference preparation were as follows:tmax were (2.60±0.67) h and (2.60±0.50) h,Cmax were (2 767.90±9 69.20) μg/L and (2 864.10± 1 090.2) μg/L,t1/2 were (1.80±0.60) h and (1.80±0.50) h,AUC0→t were (8 071.10±4 747.90) μg.h/L and (8 272.50±5 095.00) μg.h/L,AUC0→∞ were (8 581.60±5 255.70) μg.h/L and (8 803.30±5 639.10) μg.h/L,respectively. The relative bioavailability of test preparation was (99.40±11.40)%. Conclusion:Statistical analysis showes Pantoprazole sodium enteric-coated Capsules test preparation and reference preparation were bioequivalent in Chinese healthy volunteers.
Keywords:Pantoprazole sodium enteric-coated Capsules  Chromatography  HPLC  Pharmacokinetics  Bioequiavalence
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号